HDL cholesterol and cardiovascular risk

BMJ (Online)

Volumn 338, Issue 7693, 2009, Pages

  Ghali, William A ^a   Rodondi, Nicolas ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN; TORCETRAPIB;

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG SAFETY; HEART VENTRICLE EXTRASYSTOLE; HORMONE SUBSTITUTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; RISK FACTORS;

EID: 84859001144     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.a3065     Document Type: Review

References (12)

1. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.[Abstract/Free Full Text]
2. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham heart study. Ann Intern Med 1992;117:990-6.[Sl][Medline]
3. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Frederiksen BS, Davanlou M, et al. Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age 55 or older. Am J Cardiol2006:97:1351-7.[CrossRef][Sl][Medline]
4. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.[Abstract]
5. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97. [Abstract/Free Full Text]
6. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007:154:943-53.[CrossRef][Sl][Medline]
7. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007:356:1304-16.[Abstract/Free Full Text]
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13. [Abstract/Free Full Text]
9. DeGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008;51:2199- 211.[Abstract/Free Full Text]
10. Sofi F, Cesari F, Abbate R, Gensini GF, Gasini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008;337:a1344[Abstract/Free Full Text]
11. Manson JE, Hu FB, Rich-Edwards JW, Colditz GA, Stampfer MJ, Willett WC, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650-8 [Abstract/Free Full Text]
12. ACCORD. ACCORD purpose. 2006. www.accordtrial.org/public/index.cfm.